PaxMedica Inc

-0.0101 (-0.7%)


Draw Mode:

Volume 64,830
Bid Price 1.41
Ask Price 1.43
News -
Day High 1.4721


52 Week Range


Day Low 1.4194
Company Name Stock Ticker Symbol Market Type
PaxMedica Inc PXMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0101 -0.7% 1.4299 19:53:23
Open Price Low Price High Price Close Price Prev Close
1.42 1.4194 1.4721 1.44 1.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
330 64,830 $ 1.44 $ 93,082 - 1.2618 - 10.48
Last Trade Time Type Quantity Stock Price Currency
19:53:23 formt 143 $ 1.4299 USD

PaxMedica Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 20.90M 14.62M 4.67M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -269.46k 1.90%

more financials information »

PaxMedica News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PXMD Message Board. Create One! See More Posts on PXMD Message Board See More Message Board Posts

Historical PXMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.451.601.381.50173,505-0.0201-1.39%
1 Month1.571.751.26181.51274,359-0.1401-8.92%
3 Months1.962.851.26182.141,154,212-0.5301-27.05%
6 Months2.304.071.26182.41913,296-0.8701-37.83%
1 Year6.5010.481.26183.431,730,687-5.07-78.0%
3 Years6.5010.481.26183.431,730,687-5.07-78.0%
5 Years6.5010.481.26183.431,730,687-5.07-78.0%

PaxMedica Description

PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes.